What is Belharra Therapeutics?
Founded in 2021, Belharra Therapeutics operates at the intersection of advanced chemical biology and drug discovery. The company is dedicated to mapping the proteome to identify previously undruggable targets, a strategy that distinguishes it from traditional pharmaceutical research firms. By focusing on high-impact therapeutic areas, Belharra aims to address significant unmet medical needs through precision-engineered molecules. Its headquarters in San Mateo, California, places it at the heart of a global innovation hub, allowing the company to tap into a deep pool of scientific talent and collaborative research opportunities. The firm's operational focus remains on building a robust, scalable platform that can consistently deliver high-value assets to the biopharmaceutical market.
How much funding has Belharra Therapeutics raised?
Belharra Therapeutics has raised a total of $130M across 1 funding round:
Other Financing Round
$130M
Other Financing Round (2023): $130M with participation from Genentech and Versant Ventures
Key Investors in Belharra Therapeutics
Genentech
Genentech is a pioneering biotechnology company specializing in the research and development of innovative biopharmaceuticals to address serious medical conditions.
Versant Ventures
Versant Ventures is a prominent venture capital firm that partners with entrepreneurs to build and fund innovative biotechnology companies globally.
Undisclosed Investors
What's next for Belharra Therapeutics?
Looking ahead, the strategic roadmap for Belharra Therapeutics involves the aggressive expansion of its internal research programs and the potential for further collaborative partnerships. The recent capital infusion will likely be directed toward enhancing the company's proprietary technology stack and increasing the throughput of its discovery engine. As the firm matures, the focus will shift toward clinical validation and the establishment of a more comprehensive intellectual property portfolio. Investors and industry observers will be closely monitoring the company's ability to translate its early-stage scientific breakthroughs into tangible clinical outcomes, which will be essential for securing future growth and long-term commercial viability in the global drug development market.
See full Belharra Therapeutics company page
